Compare · ETON vs LLY
ETON vs LLY
Side-by-side comparison of Eton Pharmaceuticals Inc. (ETON) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ETON and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.09T, about 1056.4x ETON ($1.03B).
- Over the past year, ETON is up 160.0% and LLY is up 49.6% - ETON leads by 110.4 points.
- LLY has been more active in the news (8 items in the past 4 weeks vs 4 for ETON).
- LLY has more recent analyst coverage (25 ratings vs 6 for ETON).
- Company
- Eton Pharmaceuticals Inc.
- Eli Lilly and Company
- Price
- $37.52+0.19%
- $1154.26-2.51%
- Market cap
- $1.03B
- $1.09T
- 1M return
- +16.94%
- -0.54%
- 1Y return
- +160.01%
- +49.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 4
- 8
- Recent ratings
- 6
- 25
Eton Pharmaceuticals Inc.
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. It also develops ET-105, a lamotrigine for oral suspension; DS-300, a cysteine injection; DS-100, a dehydrated alcohol injection; ET-104, a zonisamide oral suspension; ET-101, a topiramate oral suspension; and ET-203, an ephedrine ready-to-use injection. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest ETON
- President & CEO Brynjelsen Sean exercised 227,500 shares at a strike of $1.20, increasing direct ownership by 27% to 1,061,194 units (SEC Form 4)
- Chief Business Officer Krempa David converted options into 10,000 shares, increasing direct ownership by 37% to 37,025 units (SEC Form 4)
- Large owner Opaleye Management Inc. sold $4,768,637 worth of shares (126,685 units at $37.64) (SEC Form 4)
- SEC Form 4 filed by Chief Business Officer Krempa David
- Director Adams Jennifer Mckie exercised 50,000 shares at a strike of $3.78 and sold $1,623,795 worth of shares (50,000 units at $32.48) (SEC Form 4)
- Eton Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 3 filed by new insider Matthews Judith M.
- President & CEO Brynjelsen Sean sold $3,825,717 worth of shares (120,000 units at $31.88), decreasing direct ownership by 13% to 833,694 units (SEC Form 4)
- SEC Form 144 filed by Eton Pharmaceuticals Inc.
- Chief Business Officer Krempa David exercised 87,794 shares at a strike of $2.32 and sold $3,229,923 worth of shares (100,000 units at $32.30), decreasing direct ownership by 33% to 25,249 units (SEC Form 4)
Latest LLY
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend
- International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.15% to 2,995 units (SEC Form 4)
- Director Luciano Juan R was granted 14 shares, increasing direct ownership by 0.08% to 16,891 units (SEC Form 4)